Publications in collaboration with researchers from Hospital Regional Universitario de Málaga (9)

2021

  1. Impact of the COVID-19 pandemic on the care of cancer patients in Spain

    ESMO open, Vol. 6, Núm. 3, pp. 100157

2018

  1. A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

    Lung Cancer, Vol. 120, pp. 27-33

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

  2. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 317, Núm. 18, pp. 1844-1853

  3. Surgical treatment of low and intermediate grade lung net

    Journal of Thoracic Disease, Vol. 9, pp. S1435-S1441

2014

  1. Atypical carcinoid tumours of the lung: Prognostic factors and patterns of recurrence

    Thorax, Vol. 69, Núm. 7, pp. 648-653

2013

  1. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

    Lung Cancer, Vol. 81, Núm. 1, pp. 84-90

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

  1. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

    Lung Cancer, Vol. 72, Núm. 1, pp. 84-91